Diabetes Researchers Await Verdict in Closed Virtual Room
Published Date: 3/26/2025
Notice
Summary
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a private virtual meeting on April 11, 2025, to review grant applications. This meeting affects researchers seeking funding for diabetes, digestive, and kidney disease studies. No public access or money changes are involved, but the review helps decide which projects get support.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Closed NIH Grant Review Meeting
On April 11, 2025 from 11:00 a.m. to 12:30 p.m., the National Institute of Diabetes and Digestive and Kidney Diseases will hold a virtual meeting closed to the public to review and evaluate grant applications. The meeting is to decide which diabetes, digestive, and kidney research projects may receive support and will remain confidential because applications could disclose trade secrets or personal information. No public access or changes to funding amounts are stated in the notice.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17687, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in October 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, ensuring fair and confidential decisions. Scientists applying for grants in genetics, molecular sciences, oral health, and cancer research are the ones affected, with no direct cost changes announced.
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
Previous / Next Documents
Previous: 2025-05085, National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting.
The National Institute of Neurological Disorders and Stroke is holding a closed virtual meeting on April 18 and 22, 2025, to review important grant applications. This meeting affects researchers seeking funding for brain and nerve studies, ensuring their ideas stay private and protected. No public access means the review process stays fair and secure, helping decide who gets money to push science forward.
Next: 2025-05088, Codex Alimentarius Commission: Meeting of the Codex Committee on Contaminants in Foods
The U.S. Codex Office is hosting a public meeting on May 29, 2025, to share info and gather feedback on food safety topics before the big Codex Committee meeting in Bangkok this June. This affects food producers, regulators, and anyone interested in keeping our food safe from contaminants. The meeting helps shape rules that could impact trade and food safety standards worldwide.